Akero Therapeutics (AKRO) stock surged 5.82% in pre-market trading on Tuesday, fueled by analyst optimism following the release of promising late-stage trial data for the company's investigational drug efruxifermin.
Multiple analysts raised their price targets and reiterated Buy/Overweight ratings on AKRO, citing the positive 96-week results from the SYMMETRY trial evaluating efruxifermin for the treatment of non-alcoholic steatohepatitis (NASH).
Notably, Morgan Stanley significantly increased its price target to $96 from $46, with analysts highlighting efruxifermin's potential to capture significant market share and achieve commercial success if approved. Analysts at Canaccord Genuity, Citigroup, and H.C. Wainwright also raised their price targets, maintaining Buy ratings on the stock.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。